Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 38 matching trials from the live ClinicalTrials.gov search.
Conditions
Primary Membranous Nephropathy
Interventions
Zanubrutinib, Tacrolimus
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Granada Hills, California • Palo Alto, California • Minneapolis, Minnesota + 1 more
Conditions
Systemic Lupus Erythematosus
Interventions
TRU-015
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Lake Success, New York + 3 more
Conditions
Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Interventions
Serum and renal tissue analysis
Other
Lead sponsor
Meyer Children's Hospital IRCCS
Other
Eligibility
0 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Primary Membranous Nephropathy
Interventions
Povetacicept, Tacrolimus
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
27
States / cities
Montgomery, Alabama • Surprise, Arizona • Los Angeles, California + 23 more
Completed Phase 2Phase 3 Interventional

Rituximab in Membranous Nephropathy

NCT00425217
Conditions
Membranous Nephropathy
Interventions
Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Treatment Resistant Nephrotic Syndrome
Interventions
ACTHAR gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Membranous Nephropathy, Nephrotic Syndrome
Interventions
Belimumab, Placebo for Belimumab, Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
Conditions
Lupus Membranous Nephropathy
Interventions
Filgotinib, Lanraplenib, Filgotinib placebo, Lanraplenib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Palo Alto, California • Gainesville, Florida + 4 more
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions
Atacicept
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brisbane, California
Conditions
IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
APL-2
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more
Conditions
Membranous Nephropathy
Interventions
Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 4 Interventional Results available

Adrenocorticotropic Hormone in Membranous Nephropathy

NCT03025828
Conditions
Membranous Nephropathy
Interventions
ACTHar
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Glomerulonephritis, Membranous
Interventions
Inebilizumab, Tacrolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 79 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
4
States / cities
Los Angeles, California • Doral, Florida • Miami, Florida + 1 more
Conditions
IgAN, LN, MN, C3G
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more